J.P. Morgan Healthcare Conference Agios Pharmaceuticals

4 Well-positioned with multiple near-term catalysts to enter multi-billion dollar markets and deliver significant value PKa franchise with multi-billion dollar potential Large opportunities with substantial value - potential for two additional first and best-in-class indications for PYRUKYND® by 2026 PK pyruvate kinase Pka pyruvate kinase activation Differentiated mechanism of action Clearly differentiated PK activation franchise targeting red blood cell health beyond hemoglobin increase Increasing probability of success Proven track record supported by compelling and consistent data to date Growing pipeline Diversified pipeline addressing the underlying pathophysiology of rare diseases with high unmet need

View entire presentation